Status:
TERMINATED
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Leukemia
Lymphoma
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Objectives: * Determine the corrected count increment of autologous transfused platelets that had been stored by cryopreservation with ThromboSol. * Determine the ability of autologous platelets that...
Detailed Description
Platelets are an important component of blood. Transfusions with platelets help to control bleeding in thrombocytopenic patients. Using the standard blood banking procedures, platelets can only be sto...
Eligibility Criteria
Inclusion
- 1\) 1.- Patients in remission with ALL, CLL, AML, CML, MDS will be allowed to participate in this program if their platelet count is \>150K, and the hemoglobin level is at least 8.0g/dl. The patient will receive their autologous platelets cryopreserved in ThromboSol or the fresh random platelets (FRP) whenever the need for such transfusions is determined to be clinically indicated by their physician(s).
Exclusion
- 1\) Patients with detectable circulating malignant cells or ongoing marrow involvement by the tumor will not be eligible.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00074763
Start Date
July 1 2003
End Date
January 1 2006
Last Update
August 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT M.D. Anderson Cancer Center
Houston, Texas, United States, 77030